Dr. Malin Hultqvist-Hopkins

Dr. Malin Hultqvist-Hopkins

Beneficiary (B7)

Dr. Malin Hultqvist Hopkins is since May 2016 CEO of Redoxis. Malin holds a PhD in Medical Inflammation Research from Lund University (Sweden) and was between 2009-2016 CSO of Redoxis and director of CRO services. Malin is also member of the board of Redoxis subsidiary ProNoxis AB, focusing on development of small molecule drugs for treatment of autoimmune conditions.

Redoxis is a CRO with core expertise and focus on preclinical drug development and efficacy evaluation in models of autoimmune diseases. With the roots in academic research we are always up to date with the latest immunology research and are continuously updating our portfolio of models.

Staying connected with academic research is important to us. We have on-going collaborations with academic partners for model development and are members of several EU funded projects aiming at developing standardized models for autoimmune conditions.

Disease models
Mouse models
Cell based assays
Biomedical research


© 2018 COSMIC. All Rights Reserved.

Please publish modules in offcanvas position.